Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Monday

Sagimet Biosciences (NASDAQ:SGMT) is expected to be issuing its Q4 2025 resultson Monday, March 30th. Analysts expect the company to announce earnings of ($0.4322) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 7:00 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last issued its earnings results on Wednesday, March 11th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Stock Down 4.3%

Shares of SGMT opened at $4.89 on Friday. The business’s 50-day moving average price is $5.52 and its 200-day moving average price is $6.45. Sagimet Biosciences has a twelve month low of $1.73 and a twelve month high of $11.41. The stock has a market cap of $159.32 million, a PE ratio of -3.11 and a beta of 3.35.

Insider Buying and Selling at Sagimet Biosciences

In related news, CEO David Happel sold 12,101 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total value of $64,861.36. Following the transaction, the chief executive officer directly owned 677,621 shares in the company, valued at approximately $3,632,048.56. This represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 14.70% of the company’s stock.

Hedge Funds Weigh In On Sagimet Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of SGMT. Affinity Asset Advisors LLC increased its holdings in shares of Sagimet Biosciences by 228.1% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock worth $6,798,000 after buying an additional 798,245 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Sagimet Biosciences by 6,484.7% during the 3rd quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock worth $5,326,000 after acquiring an additional 788,537 shares during the last quarter. Marshall Wace LLP purchased a new position in Sagimet Biosciences in the fourth quarter worth $4,620,000. Schonfeld Strategic Advisors LLC grew its position in Sagimet Biosciences by 462.4% in the third quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock worth $3,593,000 after acquiring an additional 430,644 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new position in Sagimet Biosciences in the fourth quarter valued at $1,802,000. Hedge funds and other institutional investors own 87.86% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Sagimet Biosciences in a research note on Wednesday, March 11th. Guggenheim assumed coverage on shares of Sagimet Biosciences in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $27.00 target price on the stock. Wall Street Zen raised shares of Sagimet Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Rodman & Renshaw assumed coverage on shares of Sagimet Biosciences in a report on Thursday. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Barclays assumed coverage on Sagimet Biosciences in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $8.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.25.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.